Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +0.22% 116.25p 113.00p 119.50p - - - 8,553 16:35:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.8 -2.3 - 81.40

Silence Therapeutics Share Discussion Threads

Showing 50351 to 50374 of 50375 messages
Chat Pages: 2015  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  Older
DateSubjectAuthorDiscuss
10/8/2018
20:57
hTtps://www.statnews.com/2018/08/10/fda-alnylam-rnai-patisiran-onpattro/ Time to pay up!
waterloo01
08/8/2018
17:06
hey @buywell what was the Daily Mail spin? SLN already commented on this in an RNS on the 7th. SLN are now litigating for a potentially increasingly successful use of their IP - doesn't seem like a negative to me as they were already litigating.
djnzloop
08/8/2018
14:19
piece in the Daily Mail today stockwatch didn't read too good, about this On 3 August 2018, Alnylam Pharmaceuticals Inc. ("Alnylam") announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) had granted its RNAi medicine, patisiran, a positive scientific opinion through the Early Access to Medicines Scheme. Further to this decision, Alnylam can provide eligible adults in the UK with access to patisiran before the drug is granted EU marketing authorisation by the European Commission. Grant of the EU marketing authorisation for patisiran is imminent.
buywell3
03/8/2018
14:56
CEO & CSO both quit in June without any real explanation. New CEO appears to have been made unexpectedly available - but does seem to fit the bill with a previous sale experience. I reckon the market is guessing there may be some bad news due perhaps about the pending litigation this December... also it is very frustrating watching them sell their stake in Arrowhead only to watch it soar away - perhaps some contention there??I guess some news flow would help here
djnzloop
03/8/2018
14:15
Chartwise 75p seems possible
buywell3
03/8/2018
14:10
Could anyone tell me what has happened in the last couple of weeks for the share price to have dropped about 40 points,or nearly 25%.
tshirley12
02/8/2018
17:53
htTp://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-reports-second-quarter-2018-financial No mention of SLN but they do have $1.5bn in cash!
waterloo01
31/7/2018
10:35
Hi Callumross,thanks for that info.
tshirley12
30/7/2018
23:11
From what I understand it is all technical stuff so far, such as SLN challenging jurisdiction, and it is not about "winning" as such, rather about successfully defending an action brought by ALNY. Unlike the Portugal case and the UK case to be held in December where SLN is the litigant. Will be many months before all this is cleared up and is probably a distraction from the other news such as the Quark phase 3 trials and the new clinical trials scheduled for the end of the year. Having said that, if they win some of these cases, it will make the current market cap look very cheap and remember that the most recently granted US patents do not form part of the ALNY US action.
callumross
30/7/2018
23:11
From what I understand it is all technical stuff so far, such as SLN challenging jurisdiction, and it is not about "winning" as such, rather about successfully defending an action brought by ALNY. Unlike the Portugal case and the UK case to be held in December where SLN is the litigant. Will be many months before all this is cleared up and is probably a distraction from the other news such as the Quark phase 3 trials and the new clinical trials scheduled for the end of the year. Having said that, if they win some of these cases, it will make the current market cap look very cheap and remember that the most recently granted US patents do not form part of the ALNY US action.
callumross
30/7/2018
19:25
Hi Callumross, have never posted before,but a long time share holder.Checked out your link,to be honest I don't understand all the legal technicalities,Put simply in your opinion are we winning or not.
tshirley12
30/7/2018
16:02
Link to ongoing US Court case; https://www.pacermonitor.com/public/case/24076996/Alnylam_Pharmaceuticals,_Inc_v_Silence_Therapeutics_GmbH_et_al
callumross
18/7/2018
23:29
The results of this could potentially move SLN higher later in the year; "The same molecule QPI-1002 also completed dosing of 594 patients in a pivotal Phase 3 study (QRK306, NCT02610296) for delayed graft function (DGF) following kidney transplantation in January 2018. As in the AKI trial, the company reached agreement with the FDA on the overall Phase 3 trial design with a new innovative primary endpoint for DGF, based on the DGF Phase 2 data (QRK006, NCT00802347). We anticipate receiving the first interpretative results (FIR) in the fourth quarter of 2018."
callumross
11/7/2018
07:21
Good lord, even I remember this Quark trial from many years ago. Anyone remember the details of milestone payments ?
waterloo01
11/7/2018
07:18
Good to see the Phase 3 AKI trial has finally made it to an rns. I was beginning to think they weren't going to bother.
1gw
06/7/2018
14:08
After many years absence I bought a few over the last few days. Doesn't take much to move. My reasoning for buying now is less what SLN are doing (very little over the years) but that the combination of new blood and more particularly Alnylam's trail progress. My 'hope' is that they make SLN disputes go away by buying them out. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis htTps://www.nejm.org/doi/full/10.1056/NEJMoa1716153
waterloo01
06/7/2018
13:00
Seems like a good bounce for such low volume. Still, not complaining.
1gw
20/6/2018
21:50
Thanks callumross. She looks pretty full-on, i.e. fully engaged in what Silence is doing - so that's good. She presented Ali's departure as a Silence-led thing - time for a person with a different skillset to take over now that Ali had got the company capitalised and largely staffed up. She didn't strike me as someone who thought she was in the executive role purely in an interim capacity. I thought she was going to go the whole interview without mentioning the patent litigation but did comment when prompted towards the end. Sounds like we should expect to hear some news on a "partnership" before too long - i.e. another company licensing or in some other way coming on board the Silence platform. Let's hope so. And good to see that the Nasdaq listing and other shareholder-pleasing moves are still under consideration.
1gw
20/6/2018
16:09
Interesting Callum
volsung
20/6/2018
13:44
http://www.proactiveinvestors.co.uk/companies/stocktube/9554/silence-therapeutics-in-a-hot-space-with-few-competitors--9554.html
callumross
04/6/2018
22:11
I see it as either he's decided that he's done all he can & is now following a more promising/interesting avenueOrThere's something interesting short term brewing.Whatever. I said to myself when he or gang lost interest I was out but I am currently intrigued. I may well pay for that view
djnzloop
04/6/2018
21:44
Very strange shareprice move given the news. Good volume for recent months, but pretty small as a % of the share capital. I can't see that losing Ali in such an apparently unplanned way is at all positive. I presume he had a lot to do with the strategy around both the ARWR stake and the patent litigation, and although ARWR was successfully disposed of, the patent litigation / negotiation could have a long way still to run. So I wonder if it was an existing shareholder deciding to buy back having previously sold some in anticipation of something along these lines happening. Because it's equally unclear to me why the price should have fallen so quickly from its £2 base in the first place. While I did wonder when her appointment as (non-exec) Chair was announced if Annalisa Jenkins was being lined up for an executive role at Silence once the Dimension sale was finished, she was snapped up by Plaquetec in November (link below). I don't see how she can successfully combine the roles of Plaquetec CEO and Silence Executive Chair for long (is Plaquetec going to be compensated if she has to go part-time there for a while?), so perhaps she thinks Silence is close to landing a good candidate for the CEO role. Unless of course, Ali going is the price of closing a deal with Alny or someone else, and everyone involved knows who is going to be in charge when the deal does close - but that seems a bit far-fetched. hTtps://www.prnewswire.com/news-releases/plaquetec-announces-the-appointment-of-annalisa-jenkins-mbbs-frcp-as-chief-executive-officer-657181603.html
1gw
04/6/2018
12:26
Or if Ali sells on his stake, to whom?
callumross
04/6/2018
12:20
Perhaps the fall from 200p was due at least in part to some selling on a rumour of this event? And now we're getting some buying on the news?
1gw
Chat Pages: 2015  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180815 01:11:36